The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
Open accessAbstract
PD-1, a member of the CD28 family of immune regulatory molecules, is expressed on activated T cells, interacts with its ligands, PD-L1/B7-H1 and PD-L2/B7-DC, on other cells, and delivers inhibitory signals to the T cell. We studied the role of this pathway in modulating autoreactive T cell responses in two models of myocarditis. In a CD8+ T cell-mediated adoptive transfer model, we found that compared with Pd1+/+ CD8+ T cells, Pd1−/− CD8+ T cells cause enhanced disease, with increased inflammatory infiltrate, particularly rich in neutrophils. Additionally, we show enhanced proliferation in vivo and enhanced cytotoxic activity of PD-1–deficient T lymphocytes against myocardial endothelial cells in vitro. In experimental autoimmune myocarditis, a disease model dependent on CD4+ T cells, we show that mice lacking PD-1 develop enhanced disease compared with wild-type mice. PD-1–deficient mice displayed increased inflammation, enhanced serum markers of myocardial damage, and an increased infiltration of inflammatory cells, including CD8+ T cells. Together, these studies show that PD-1 plays an important role in limiting T cell responses in the heart.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this finding was not recapitulated in a separately generated PD-1 genetic knockout mouse model in a BALB/c background”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“anti-cTnI IgG levels were not significantly elevated in the ICI myocarditis mouse model induced with anti-PD-1 antibody treatment.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, this finding was not replicated in other researchers' investigations”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [98]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Self-citationT cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Self-citationTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785
Self-citationSharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759
Self-citationTissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,244
Self-citationGood‐Jacobson, K. L., Szumilas, C. G., Chen, L., Sharpe, A. H., Tomayko, M. M., & Shlomchik, M. J. (2010) · Nature Immunology · doi:10.1038/ni.1877 · Cited by 720
Self-citation
Cited by
Sorted by citations
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Self-citationLinette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L. A., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,209
Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease
Re, D. P. D., Amgalan, D., Linkermann, A., Liu, Q., & Kitsis, R. N. (2019) · Physiological Reviews · doi:10.1152/physrev.00022.2018 · Cited by 994
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590
Immune checkpoint inhibitors and cardiovascular toxicity
Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 495
Role of the PD-1 pathway in the immune response
Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444
“PD-1 deficiency on self antigen-specific T cells increases CD8 T cell responses to antigen-bearing resting DCs, and abrogates CD8 T cell tolerance to peripheral self-antigen expression in vivo (30,31,61).”
BackgroundSelf-citationImmune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Touat, M., Maisonobe, T., Knauß, S., Salem, O. B. H., Hervier, B., Auré, K., Szwebel, T., Kramkimel, N., Lethrosne, C., Bruch, J.-F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006124 · Cited by 341
Laubli, H. P., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 321
Left Ventricular T-Cell Recruitment Contributes to the Pathogenesis of Heart Failure
Nevers, T. A., Salvador, A. M., Grodecki‐Pena, A., Knapp, A., Velázquez, F., Aronovitz, M. J., Kapur, N. K., Karas, R. H., Blanton, R. M., & Alcaide, P. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002225 · Cited by 281
Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
Gianchecchi, E., Delfino, D. V., & Fierabracci, A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.003 · Cited by 277
PD-1/PD-L and autoimmunity: A growing relationship
Zamani, M. R., Aslani, S., Salmaninejad, A., Javan, M. R., & Rezaei, N. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.09.009 · Cited by 276
Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones‐Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.025 · Cited by 273
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
Self-citationCardiac Autoimmunity: Myocarditis
Bracamonte-Baran, W., & Čiháková, D. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-57613-8_10 · Cited by 228
Cardiovascular Toxicities of Immune Checkpoint Inhibitors
Ball, S., Ghosh, R. K., Wongsaengsak, S., Bandyopadhyay, D., Ghosh, G. C., Aronow, W. S., Fonarow, G. C., Lenihan, D. J., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.079 · Cited by 231
Pathak, R., Katel, A., Massarelli, E., Villaflor, V. M., Sun, V. C.-Y., & Salgia, R. (2021) · The Oncologist · doi:10.1002/onco.13931 · Cited by 233
Deep insight into cytokine storm: from pathogenesis to treatment
Nie, J., Zhou, L., Tian, W., Liu, X., Yang, L., Yang, X., Zhang, Y., Wei, S., Wang, D. W., & Wei, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02178-y · Cited by 251
Treating Atherosclerosis With Regulatory T Cells
Foks, A. C., Lichtman, A. H., & Kuiper, J. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303568 · Cited by 203
Self-citationSmoldering myocarditis following immune checkpoint blockade
Norwood, T. G., Westbrook, B. C., Johnson, D. B., Litovsky, S. H., Terry, N. L. J., McKee, S. B., Gertler, A. S., Moslehi, J. J., & Conry, R. M. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0296-4 · Cited by 202
Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Huang, Y. V., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056730 · Cited by 192
Frantz, S., Falcão‐Pires, I., Balligand, J., Bauersachs, J. K., Brutsaert, D. L., Ciccarelli, M., Dawson, D. K., Windt, L. J. D., Giacca, M., Hamdani, N., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1138 · Cited by 193
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy
Michel, L., Helfrich, I., Hendgen-Cotta, U. B., Mincu, R., Korste, S., Mrotzek, S. M., Spomer, A., Odersky, A., Rischpler, C., Herrmann, K., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab430 · Cited by 169
Myocarditis in Humans and in Experimental Animal Models
Błyszczuk, P. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00064 · Cited by 161
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161
Cardiotoxicity of Immune Checkpoint Inhibitors
Patel, R. P., Parikh, R. B., Gunturu, K. S., Tariq, R. Z., Dani, S. S., Ganatra, S., & Nohria, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01070-6 · Cited by 154
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies
Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.120.315894 · Cited by 138
Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137
Carrillo-Salinas, F. J., Ngwenyama, N., Anastasiou, M., Kaur, K., & Alcaide, P. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.04.009 · Cited by 135
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 135
Tocchetti, C. G., Dessalvi, C. C., Lisi, D. D., Femminò, S., Madonna, R., Mele, D., Monte, I. P., Novo, G., Penna, C. R. R., Pepe, A., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6930 · Cited by 132
Mir, H. R., Alhussein, M. M., Alrashidi, S., Alzayer, H., Alshatti, A., Valettas, N., Mukherjee, S. D., Nair, V., & Leong, D. P. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.03.012 · Cited by 124
T cell checkpoint regulators in the heart
Grabie, N., Lichtman, A. H., & Padera, R. F. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz025 · Cited by 126
Self-citationMyocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors
Ji, C., Roy, M. D., Golas, J., Vitsky, A., Ram, S., Kumpf, S. W., Martin, M. T., Barletta, F., Meier, W. A., Hooper, A. T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4083 · Cited by 122
T-cell recruitment to the heart: friendly guests or unwelcome visitors?
Blanton, R. M., Carrillo-Salinas, F. J., & Alcaide, P. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00028.2019 · Cited by 118
Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab
Tadokoro, T., Keshino, E., Makiyama, A., Sasaguri, T., Ohshima, K., Katano, H., & Mohri, M. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.116.003514 · Cited by 111
Neilan, T. G., Rothenberg, M. L., Amiri‐Kordestani, L., Sullivan, R. J., Steingart, R. M., Gregory, W. W., Hariharan, S., Hammad, T. A., Lindenfeld, J. M., Murphy, M. J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0157 · Cited by 107
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Shalata, W., Abu-Salman, A., Steckbeck, R., Jacob, B. M., Massalha, I., & Yakobson, A. (2021) · Cancers · doi:10.3390/cancers13205218 · Cited by 109
Cardiorenal complications of immune checkpoint inhibitors
Sury, K., Perazella, M. A., & Shirali, A. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0035-1 · Cited by 106
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Baraibar, I., Melero, I., Ponz‐Sarvisé, M., & Álvarez, E. C. (2019) · Drug Safety · doi:10.1007/s40264-018-0774-8 · Cited by 106
Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153
Baban, B., Liu, J. Y., Qin, X., Weintraub, N. L., & Mozaffari, M. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124059 · Cited by 101
Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 102
Liu, J., Blake, S. J., Harjunpää, H., Fairfax, K. A., Yong, M. C. R., Allen, S. M., Kohrt, H. E. K., Takeda, K., Smyth, M. J., & Teng, M. W. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0194 · Cited by 94
Chen, D., Huang, W., Wu, V. C., Chang, W., Chen, J., Chuang, C., & Chu, P. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.07.025 · Cited by 96
Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists
Frigeri, M., Meyer, P., Banfı, C., Giraud, R., Hachulla, A.-L., Spoerl, D., Friedlaender, A., Pugliesi, A., & Dietrich, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.09.025 · Cited by 95
Tocchetti, C. G., Farmakis, D. T., Koop, Y., Andrés, M. S., Couch, L. S., Formisano, L., Ciardiello, F., Pane, F., Au, L., Emmerich, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3340 · Cited by 102
Adaptive immune cells in calcific aortic valve disease
Raddatz, M. A., Madhur, M. S., & Merryman, W. D. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00100.2019 · Cited by 97
Bockstahler, M., Fischer, A., Goetzke, C. C., Neumaier, H. L., Sauter, M., Kespohl, M., Müller, A., Meckes, C., Salbach, C., Schenk, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043171 · Cited by 89
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Munir, A. Z., Gutierrez, A., Qin, J., Lichtman, A. H., & Moslehi, J. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00715-5 · Cited by 97
Self-citationCardiotoxicity of Immune Checkpoint Inhibitors
Zhang, L., Jones‐O’Connor, M., Awadalla, M., Zlotoff, D. A., Thavendiranathan, P., Groarke, J. D., Villani, A., Lyon, A. R., & Neilan, T. G. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0731-6 · Cited by 89
T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword
Simons, K. H., de Jong, A., Jukema, J. W., de Vries, M. R., Arens, R., & Quax, P. H. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0164-7 · Cited by 89
Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases
Atallah‐Yunes, S. A., Kadado, A. J., Kaufman, G. P., & Hernández-Montfort, J. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02927-x · Cited by 87
Sarocchi, M., Grossi, F., Arboscello, E., Bellodi, A., Genova, C., Bello, M. G. D., Rijavec, E., Barletta, G., Rossi, G., Biello, F., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0452 · Cited by 88
The heart of the matter: Protection of the myocardium from T cells
Lichtman, A. H. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.05.004 · Cited by 84
Self-citationManaging cardiotoxicity associated with immune checkpoint inhibitors
Upadhrasta, S., Elias, H., Patel, K., & Zheng, L. (2019) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2019.02.004 · Cited by 83
Gibson, R., Delaune, J. D., Szady, A. D., & Markham, M. J. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-216228 · Cited by 80
Exploring immune checkpoints as potential therapeutic targets in atherosclerosis
Kusters, P. J. H., Lutgens, E., & Seijkens, T. T. P. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx248 · Cited by 81
Waliany, S., Lee, D. C., Witteles, R. M., Neal, J. W., Nguyen, P. K. P., Davis, M. M., Salem, J., Wu, S. M., Moslehi, J. J., & Zhu, H. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023451 · Cited by 77
Allogenicity of Human Cardiac Stem/Progenitor Cells Orchestrated by Programmed Death Ligand 1
Lauden, L., Boukouaci, W., Borlado, L. R., López, I. P., Sepúlveda, P., Tamouza, R., Charron, D. J., & Al‐Daccak, R. (2012) · Circulation Research · doi:10.1161/circresaha.112.276501 · Cited by 78
Tajmir-Riahi, A., Bergmann, T., Schmid, M., Agaimy, A., Schuler, G., & Heinzerling, L. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000190 · Cited by 78
Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab
Yamaguchi, S., Morimoto, R., Okumura, T., Yamashita, Y., Haga, T., Kuwayama, T., Yokoi, T., Hiraiwa, H., Kondo, T., Sugiura, Y., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.03.007 · Cited by 75
New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity
Khunger, A., Battel, L., Wadhawan, A., More, A., Kapoor, A., & Agrawal, N. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00925-8 · Cited by 77
Sławiński, G., Wrona, A., Dąbrowska-Kugacka, A., Raczak, G., & Lewicka, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197195 · Cited by 76
Immune checkpoint inhibitor-related myocarditis
Tajiri, K., Aonuma, K., & Sekine, I. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx154 · Cited by 71
Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management
Asnani, A. H. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0690-1 · Cited by 69
Regulatory Role of CD4+T Cells in Myocarditis
Vdovenko, D., & Eriksson, U. (2018) · Journal of Immunology Research · doi:10.1155/2018/4396351 · Cited by 72
Okiyama, N., & Katz, S. I. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.06.005 · Cited by 68
Tay, W. T., Fang, Y., Beh, S. T., Liu, Y.-W., Hsu, L.-W., Yen, C.-J., & Liu, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072399 · Cited by 67
Owonikoko, T. K., Kumar, M., Yang, S., Kamphorst, A. O., Pillai, R. N., Akondy, R. S., Nautiyal, V., Chatwal, M. S., Book, W., Sahu, A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1918-2 · Cited by 61
Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
Wang, L., Ma, Q., Yao, R., & Liu, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106088 · Cited by 60
Emerging pharmacologic targets and treatments for myocarditis
Jensen, L. D., & Marchant, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.006 · Cited by 60
Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma
Chen, Q., Huang, D., Zhang, L., Li, Y.-Q., Wang, H., & Liu, H. (2017) · Clinical Toxicology · doi:10.1080/15563650.2017.1401079 · Cited by 60
Synthetic RORγt Agonists Enhance Protective Immunity
Chang, M. R., Dharmarajan, V., Doebelin, C., Garcia-Ordoñez, R. D., Novick, S. J., Kuruvilla, D. S., Kamenecka, T. M., & Griffin, P. R. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00899 · Cited by 59
A Century of Radiation Therapy and Adaptive Immunity
Schaue, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00431 · Cited by 57
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Cozma, A., Sporiș, N.-D., Lazăr, A.-L., Buruiană, A., Ganea, A.-M., Mălinescu, T.-V., Berechet, B. M., Fodor, A., Sitar-Tăut, A., Vlad, C. V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810948 · Cited by 61
PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
Safi, M., Ahmed, H., Al‐Azab, M., Xia, Y., Shan, X., Alradhi, M., Al-Danakh, A., Shopit, A., & Liu, J. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.09.006 · Cited by 57
Arangalage, D., Degrauwe, N., Michielin, O. A., Monney, P. A., & Özdemir, B. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102282 · Cited by 56
Eshet, Y., Baruch, E. N., Shapira‐Frommer, R., Steinberg‐Silman, Y., Kuznetsov, T., Ben‐Betzalel, G., Daher, S., Gluck, I., Asher, N., Apter, S., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0659 · Cited by 54
Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity
Zhang, J.-C., Chen, W., Alvarez, J. B., Jia, K. Q., Shi, L., Wang, Q., Zou, N., He, K., & Zhu, H. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0062-2 · Cited by 54
Autoimmune Myocarditis, Old Dogs and New Tricks.
Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51
Nso, N., Antwi‐Amoabeng, D., Beutler, B. D., Ulanja, M. B., Ghuman, J., Hanfy, A. A., Nimo-Boampong, J., Atanga, S., Doshi, R. P., Enoru, S. T., et al. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i11.584 · Cited by 51
Autoimmunity in viral myocarditis
Reddy, J., Massilamany, C., Buskiewicz, I., & Huber, S. A. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283620036 · Cited by 50
Licata, L. A., Nguyen, C. T., Burga, R. A., Falanga, V., Espat, N. J., Ayala, A., Thorn, M., Junghans, R. P., & Katz, S. C. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0313137 · Cited by 48
Bruestle, K., Hackner, K., Kreye, G., & Heidecker, B. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01278-1 · Cited by 53
Cardiotoxicities associated with immune checkpoint inhibitors
Yang, S., & Asnani, A. H. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.002 · Cited by 49
Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis
Jiménez-Alejandre, R., Ruiz‐Fernández, I., & Martín, P. (2022) · Cancers · doi:10.3390/cancers14184494 · Cited by 50
Baban, B., Liu, J. Y., & Mozaffari, M. S. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.11.004 · Cited by 46
Rubio‐Infante, N., Ramírez‐Flores, Y. A., Castillo, E. C., Lozano, O., García‐Rivas, G., & Torre‐Amione, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.851032 · Cited by 48
Immunopathogenesis and immunomodulatory therapy for myocarditis
He, W., Zhou, L. D., Xu, K., Li, H., Wang, J. J., Chen, C., & Wang, D. W. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2273-3 · Cited by 49
Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
Yang, B., Liu, T., Qu, Y., Liu, H., Zheng, S. G., Cheng, B., & Sun, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00563 · Cited by 47
Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy
Nishi, M., Wang, P., & Hwang, P. M. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316697 · Cited by 46
Liu, D., Richardson, G. D., Benli, F. M., Park, C., de Souza, J. V. B., Bronowska, A. K., & Spyridopoulos, I. (2020) · Clinical Science · doi:10.1042/cs20191213 · Cited by 47
Baik, A. H., Tsai, K. K., Oh, D. Y., & Aras, M. A. (2021) · Clinical Science · doi:10.1042/cs20200331 · Cited by 42
Liu, S., Huang, W., Yeh, H., Ko, C.-C., Shieh, H.-R., Hung, C., Chen, T.-Y., & Chen, Y.-J. (2019) · Cancers · doi:10.3390/cancers11040580 · Cited by 41
Rahouma, M., Karim, N. A., Baudo, M., Yahia, M., Kamel, M., Eldessouki, I. A., Abouarab, A., Saad, I., Elmously, A., Gray, K. D., et al. (2019) · Immunotherapy · doi:10.2217/imt-2018-0118 · Cited by 43
Ferreira, M., Pichon, É., Carmier, D., Bouquet, É., Pageot, C., Bejan‐Angoulvant, T., Campana, M., Vermès, E., & Marchand-Adam, S. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0579-9 · Cited by 37
Immune cell diversity contributes to the pathogenesis of myocarditis
Hua, X., & Song, J. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09799-w · Cited by 37
Metadata
- Authors
- Tarrio, M. L., Grabie, N., Bu, D.-X., Sharpe, A. H., & Lichtman, A. H.
- Affiliations
- Brigham and Women's Hospital (US)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-05
- Volume
- 188
- Issue
- 10
- Pages
- 4876-4884
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC3345066
- OpenAlex
- W2130852062
- Semantic Scholar
- 25f4092ea5db9b9d9a0f493ce69a14946198bed4
- Cited by
- 288
- References
- 43
- Citations by year
- 2026: 20 · 2025: 21 · 2024: 27 · 2023: 24 · 2022: 31 · 2021: 32 · 2020: 29 · 2019: 26 · 2018: 26 · 2017: 21 · 2016: 12 · 2015: 5 · 2014: 5 · 2013: 6 · 2012: 3
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Brigham and Women's Hospital
- National Institutes of Health (HL‐36028, HL56985)
- National Heart, Lung, and Blood Institute (P50HL056985, R01 HL36028, P01HL036028, R01HL087282)
- National Institute of Allergy and Infectious Diseases (R01AI040614, P01AI056299)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- PD-1, PD-L1, PD-L2, experimental autoimmune myocarditis, adoptive transfer, CD8+ T cells, CD4+ T cells, myocarditis, myocardial injury, neutrophils, T cell proliferation, cytotoxicity, immune checkpoint
- MeSH terms
- Amino Acid Sequence, Animals, Cell Movement, Cells, Cultured, Disease Models, Animal, Female, Inflammation, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Molecular Sequence Data, Myocarditis, T-Lymphocyte Subsets, Mice, Knockout, Coculture Techniques, Muscle Cells, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
